Stem Cell Authority Stock Working Capital
| SCAL Stock | USD 0.01 0.00 0.00% |
Stem Cell Authority fundamentals help investors to digest information that contributes to Stem Cell's financial success or failures. It also enables traders to predict the movement of Stem Pink Sheet. The fundamental analysis module provides a way to measure Stem Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stem Cell pink sheet.
Stem |
Stem Cell Authority Company Working Capital Analysis
Stem Cell's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Stem Cell Authority has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Medical Care Facilities (which currently averages 0.0) industry. The working capital for all United States stocks is 100.0% higher than that of the company.
Stem Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stem Cell's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Stem Cell could also be used in its relative valuation, which is a method of valuing Stem Cell by comparing valuation metrics of similar companies.Stem Cell is currently under evaluation in working capital category among its peers.
Stem Fundamentals
| Return On Asset | 0.49 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.55 % | |||
| Current Valuation | 9.15 M | |||
| Shares Outstanding | 348.71 M | |||
| Price To Earning | 2.00 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 3.33 M | |||
| Gross Profit | 2.27 M | |||
| Net Income | 1.83 M | |||
| Cash And Equivalents | 39.84 K | |||
| Total Debt | 675.1 K | |||
| Debt To Equity | 4.88 % | |||
| Current Ratio | 1.12 X | |||
| Earnings Per Share | 0.01 X | |||
| Beta | -71.45 | |||
| Market Capitalization | 2.34 M | |||
| Total Asset | 3.99 M | |||
| Z Score | 1.8 | |||
| Net Asset | 3.99 M |
About Stem Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stem Cell Authority's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stem Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stem Cell Authority based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.